divislab glp-1 novo nordisk Finds Medicare Patients Prefer Pill Over Shot for Weight Loss Medicare to start offering weight

Glucagon-like peptide-1 receptor agonists show promise for reducing apnea-hypopnea index and body weight in patients with obstructive sleep apnea, offering new treatment options beyond PAP therapy.

A measured response to an alarming article

Revising our earlier interpretation of SELECT trial data in light of new analyses

Convenient & Easy to Use: This natural fiber supplement powder dissolves easily in water

Ensuring equitable access and strengthening health systems will be essential to prevent widening health disparities.AgendaCo-chairsDr Luz de Regil Director, Department of Nutrition and Food Safety, WHO and Dr Kirsten Bibbins Domingo Editor-in-Chief, JAMAModeratorDr Gaya Manori Gamhewage, Director, Department of Communication, WHOWelcomingDr Luz De Regil Director NFS, WHO and Dr Kirsten Bibbins-Domingo, Editor-in-Chief, JAMAPresentation:WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adultsDr Francesca Celletti, Senior Advisor Obesity, Department of Nutrition and Food Safety, WHO and Dr